AstraZeneca withdraws COVID-19 vaccine
By Steve Goldstein
AstraZeneca said it's withdrawing its COVID-19 vaccine worldwide, with the company saying there's a surplus of available vaccines that are available.
On Tuesday, the European Medicines Agency said the vaccine was no longer authorized for use after the voluntary withdrawal.
AstraZeneca (AZN) (UK:AZN) said its vaccine was a "critical component of ending the pandemic." It was developed with Oxford University and produced by the Serum Institute of India as Covishield.
Sales of what AstraZeneca called Vaxzevria were just $12 million last year, compared to $1.88 billion in 2022.
The drugmaker's vaccine - as well as the similar Johnson & Johnson vaccine - has been linked with blood clots, according to the European Medicines Agency. This could be fatal in some cases. AstraZeneca is facing a class-action lawsuit in the U.K., in which damages of up to GBP100 million are being sought, according to reports.
-Steve Goldstein
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
05-08-24 0847ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
These Stocks Are (Still) Powering the Bull Market
-
5 Undervalued Energy Stocks to Play the AI Data Center Demand Boom
-
After Earnings, Is Lowe’s Stock a Buy, Sell, or Fairly Valued?
-
5 Stocks With the Largest Fair Value Estimate Cuts After Q1 Earnings
-
10 Stocks With the Largest Fair Value Estimate Increases After Q1 Earnings
-
Markets Brief: Inflation Back in the Spotlight
-
AI Is Booming, but Consumer Spending Is Slowing. Which Will Prevail in the Stock Market?
-
What’s Happening In the Markets This Week
-
3 Dividend Stocks for June 2024
-
After Earnings, Is Alibaba Stock a Buy, Sell, or Fairly Valued?
-
MongoDB Earnings: Slashing Valuation as Execution and Macro to Blame for Lower Guidance
-
Marvell Earnings: We Raise Our Medium-Term AI Forecast and Bring Our Valuation Up to $75
-
Zscaler Earnings: Impressive Traction in Emerging Products Drives Sales Growth for the Quarter
-
Dell Earnings: Raising Valuation on Strong AI, but the Stock Remains Severely Overvalued
-
After Earnings, Is Nvidia Stock a Buy, Sell, or Fairly Valued?
-
The 10 Best Companies to Invest in Now